This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...

1Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania. 2Abramson Cancer Center and Abramson Family Cancer Research Institute, University of ...

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

In a letter addressed to NIH director Jay Bhattacharya, MD, dubbed the Bethesda Declaration, NIH staff members criticized many of the agency’s actions under the Trump administration. Representing all ...

Radiation Research Program, Division of Cancer Treatment and Diagnosis, NCI, Bethesda, Maryland. *Corresponding Author: Jeffrey C. Buchsbaum, Radiation Research Program, Division of Cancer Treatment ...

Findings from a phase I/II trial provide clinical proof-of-concept for a first-in-class mRNA-encoded T-cell engager targeting CLDN6 and CD3. Produced in vivo, the bispecific was well tolerated and had ...

SYNC-T, an investigational approach combining in situ vaccination, via partial tumor cryolysis, with intratumoral delivery of a cocktail of four immunotherapy agents, appears highly effective in ...

Cancer Res (2024) 84 (6_Supplement): 973. Addition of ENZ or AAP to androgen deprivation therapy (ADT) as first-line treatment for advanced prostate cancer improves survival compared to ADT alone.

Major Finding: Serotonin transporter depletes intratumoral serotonin which dampens CD8 + T-cell antitumor immunity. Concept: Serotonin transporter inhibition with SSRIs drives T-cell antitumor ...

*Corresponding Author: Mara H. Sherman, Cancer Biology & Genetics, Memorial Sloan Kettering Cancer Center, 417 East 68th Street, 1261, New York, NY 10065. E-mail: [email protected] ...

Cancer Res (2023) 83 (8_Supplement): LB320. QTX3034 has good solubility, permeability, and moderate protein binding in human plasma. The systemic clearance in rats and dogs was moderate to high, ...

The FDA today approved Bayer’s darolutamide (Nubeqa) for metastatic castration-sensitive prostate cancer (mCSPC) with or without chemotherapy. The decision was based on the results of the phase III ...